Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06572384
Registration number
NCT06572384
Ethics application status
Date submitted
16/08/2024
Date registered
27/08/2024
Date last updated
24/06/2025
Titles & IDs
Public title
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Query!
Scientific title
A Phase 3, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belimumab Administered Subcutaneously in Adults With Interstitial Lung Disease (ILD) Associated With Connective Tissue Disease (CTD)
Query!
Secondary ID [1]
0
0
2024-513018-36-00
Query!
Secondary ID [2]
0
0
221672
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
BEconneCTD-ILD
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Lung Diseases, Interstitial
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Other - Belimumab
Other interventions - Placebo
Experimental: Belimumab - Participants will receive belimumab in addition to standard therapy.
Placebo comparator: Placebo - Participants will receive placebo in addition to standard therapy.
Treatment: Other: Belimumab
Belimumab will be administered.
Other interventions: Placebo
Placebo will be administered.
Query!
Intervention code [1]
0
0
Treatment: Other
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Absolute Change from Baseline in Forced Vital Capacity (FVC) milliliter (mL) at Week 52
Query!
Assessment method [1]
0
0
Forced vital capacity is the total amount of air exhaled during the lung function test. Low FVC (mL) reflects more impaired lung function. Absolute Change from Baseline in FVC will be reported.
Query!
Timepoint [1]
0
0
Baseline and Week 52
Query!
Secondary outcome [1]
0
0
Absolute Change from Baseline in FVC Percentage (%) Predicted at Week 52
Query!
Assessment method [1]
0
0
FVC are expressed as a percentage of the predicted normal for a person of the same sex, age, and height. Lower % predicted FVC (mL) reflects more impaired lung function.
Query!
Timepoint [1]
0
0
Baseline and Week 52
Query!
Secondary outcome [2]
0
0
Time to ILD Progression or Death
Query!
Assessment method [2]
0
0
Time taken for a participant to experience ILD progression or death.
Query!
Timepoint [2]
0
0
From the date of assignment (Day 1) until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 52 Weeks
Query!
Secondary outcome [3]
0
0
Absolute Change from Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Score at Week 52
Query!
Assessment method [3]
0
0
The FACIT-Fatigue is a short, 13-item questionnaire that assesses self-reported fatigue and its associated impact for daily activities over the past 7 days. The scale range is from 0 to 52, with 0 being the worst possible score and 52 being the best possible score (indicating less/no fatigue).
Query!
Timepoint [3]
0
0
Baseline and Week 52
Query!
Secondary outcome [4]
0
0
Absolute Change from Baseline in Living with Pulmonary Fibrosis (L-PF) Total Symptom Score at Week 52
Query!
Assessment method [4]
0
0
The L-PF questionnaire is a 49-item questionnaire with two modules: 1) symptoms (28 items) and 2) impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough and 3) fatigue as well as a total Symptoms score. Participants rate the severity of their symptoms in the last 24 hour on a 5-point rating scale. Scoring is performed as a summary score, the mean of the dimension ratings multiplied by 100. Summary scores range from 0-100, with the higher the score the greater the impairment.
Query!
Timepoint [4]
0
0
Baseline and Week 52
Query!
Secondary outcome [5]
0
0
Absolute Change from Baseline in Quantitative Interstitial Lung Disease in the Whole Lung (QILD-WL) At Week 52
Query!
Assessment method [5]
0
0
Change from baseline in extent of architectural distortion (fibrosis), ground glass opacification, and honeycombing features on High-resolution computed tomography (HRCT) as measured by computer-aided analysis tools. Extent of ILD is calculated by summing pixel counts and expressing this as a percentage of the whole lung. ILD extent can range from 0-100% with higher percentage representing more extensive ILD.
Query!
Timepoint [5]
0
0
Baseline and Week 52
Query!
Secondary outcome [6]
0
0
Absolute Change from Baseline in Quantitative Measures of Lung Fibrosis (QLF) in the Whole Lung At Week 52
Query!
Assessment method [6]
0
0
Change from baseline in extent of reticular patterns with architectural distortion (fibrosis) on HRCT as measured by computer-aided analysis tools. Extent of fibrosis is calculated by summing pixel counts and expressing this as a percentage of the whole lung. Fibrosis extent can range from 0-100% with higher percentage representing more extensive fibrosis.
Query!
Timepoint [6]
0
0
Baseline and Week 52
Query!
Secondary outcome [7]
0
0
Achieving Greater than or Equal (=) 2% Decrease in QILD-WL Score at Week 52
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Up to Week 52
Query!
Secondary outcome [8]
0
0
Achieving Relative Decline from Baseline in FVC (mL) = 5% at Week 52
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Baseline and Week 52
Query!
Secondary outcome [9]
0
0
Achieving Relative Decline from Baseline in FVC (mL) = 10% at Week 52
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Baseline and Week 52
Query!
Secondary outcome [10]
0
0
Absolute Change from Baseline in Steroid Dose (Prednisone Equivalent Dose) at Week 52
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Baseline and Week 52
Query!
Secondary outcome [11]
0
0
Time to Connective Tissue Disease Progression
Query!
Assessment method [11]
0
0
Time taken for a participant to experience CTD progression.
Query!
Timepoint [11]
0
0
Up to 52 Weeks
Query!
Secondary outcome [12]
0
0
Absolute Change from Baseline in Transition Dyspnea Index (TDI) at Week 52
Query!
Assessment method [12]
0
0
TDI assess dyspnea severity at baseline and its change over time. TDI includes 3 components: functional impairment, magnitude of task and magnitude of effort. Each component has 7 grades, ranging from -3 (major deterioration) to +3 (major improvement), which are summed to calculate a score, ranging between - 9 and +9. Lower score indicates more severely the participant is affected by dyspnea.
Query!
Timepoint [12]
0
0
Baseline and Week 52
Query!
Secondary outcome [13]
0
0
Absolute Change from Baseline in Short Form Health Survey 36-Item Version 2 (SF36-v2) at Week 52
Query!
Assessment method [13]
0
0
The SF-36 yields an 8-scale profile of functional health and well-being scores as well as physical and mental component health summary scores. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score (0) the more disability.
Query!
Timepoint [13]
0
0
Baseline and Week 52
Query!
Secondary outcome [14]
0
0
Absolute Change from Baseline in Living with Pulmonary Fibrosis (L-PF) Impacts Total Score at Week 52
Query!
Assessment method [14]
0
0
The L-PF questionnaire is a 49-item questionnaire with two modules: 1) symptoms (28 items) and 2) impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough and 3) fatigue as well as a total Symptoms score. Participants rate the severity of their symptoms in the last 24 hour on a 5-point rating scale. Scoring is performed as a summary score, the mean of the dimension ratings multiplied by 100. Summary scores range from 0-100, with the higher the score (100) the greater the impairment.
Query!
Timepoint [14]
0
0
Baseline and Week 52
Query!
Secondary outcome [15]
0
0
Absolute Change from Baseline in Kings Brief Interstitial Lung Disease Questionnaire (K-BILD) at Week 52
Query!
Assessment method [15]
0
0
The King's Brief Interstitial Lung Disease (K- ILD) questionnaire consists of 15 items (assessed by the patients on a scale ranging from 1 to 7, where 1 and 7 represent worst and best health status). Items are compiled into 3 domains: breathlessness and activities (range: 0-21), psychological (range: 0-34) , and chest symptoms (range: 0-8). Scores are transformed to a range of 0-100 by using logit values (higher scores indicate better health status). A total score and 3 domain scores are calculated ranging from 0-100 with greater scores (100) denoting better quality of life.
Query!
Timepoint [15]
0
0
Baseline and Week 52
Query!
Secondary outcome [16]
0
0
Absolute Change from Baseline in Physician Global Assessment (PhGA) at Week 52
Query!
Assessment method [16]
0
0
The PhGA is a score which enables the treating physician to rate the participants disease on a scale from 0 to 10, where higher score (10) indicates greater severity.
Query!
Timepoint [16]
0
0
Baseline and Week 52
Query!
Secondary outcome [17]
0
0
Absolute Change in Patient Global Impression of Change (PGIC)-ILD at Week 52
Query!
Assessment method [17]
0
0
The PGIC contains two items, a global question asking participants to rate their overall change in ILD severity since first starting this study using a 7-point verbal rating scale, and a yes/no question asking participants to indicate whether the change is meaningful from their perspective.
Query!
Timepoint [17]
0
0
Baseline and Week 52
Query!
Secondary outcome [18]
0
0
Absolute Change from Baseline in Diffusing Capacity of the Lung for Carbon Monoxide (DLco) % Predicted at Week 52
Query!
Assessment method [18]
0
0
Query!
Timepoint [18]
0
0
Baseline and Week 52
Query!
Secondary outcome [19]
0
0
Number of Participants with Adverse Events (AEs), Adverse Events of Special Interest (AESIs) Serious Adverse Events (SAEs)
Query!
Assessment method [19]
0
0
Query!
Timepoint [19]
0
0
Up to Week 60
Query!
Secondary outcome [20]
0
0
Number of Participants with Respiratory Related Hospitalizations up to Week 52
Query!
Assessment method [20]
0
0
Query!
Timepoint [20]
0
0
Up to Week 52
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
* Documented diagnosis of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM; including polymyositis, dermatomyositis, anti-synthetase syndrome), Sjogren's syndrome (pSS), or mixed connective tissue disease (MCTD) in accordance with internationally recognized classification criteria
* Diagnosis of ILD on High Resolution Computed Tomography (HRCT) with disease extent of greater than or equal to (=) 10% of the whole lung (WLILD)
* Evidence of ILD progression in the previous 24 months
* Must be currently receiving stable standard therapy to manage ILD and/or underlying CTD, or to have failed or failed to tolerate first line standard therapy.
* Participant is capable and willing to self-administer the study medication or has a caregiver who is capable and willing to administer the study medication throughout the study
* A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:
* Is a woman of nonchildbearing potential (WONCBP) OR
* Is a Woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective, with a failure rate of less than (<)1%
* Capable of giving signed informed consent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
* Diagnosis of ILD other than CTD-ILD.
* Primary diagnosis of Systemic Sclerosis (SSc).
* Participants with rapidly progressive disease (absolute drop of 10% or more of FVC between screening and baseline visit and/or recent pulmonary hospitalization).
* FVC = 45% of predicted, or a Diffusing Capacity of the lung for Carbon Monoxide (DLco) (corrected for hemoglobin) = 40% of predicted at screening
* History or presence of diffuse alveolar hemorrhage (DAH) or other confounding pulmonary disease, signs, or symptoms
* Pulmonary arterial hypertension requiring therapy, as determined by the investigator at, or prior to first day of dosing (Day 1)
* Dependence on continuous oxygen supplementation
* History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data
* Obstructive pulmonary disease (pre-bronchodilator Forced Expiratory Volume (FEV1) /FVC <0.7).
* Significant emphysema on screening or historical HRCT (extent of emphysema exceeds extent of ILD)
* Confirmed Progressive multifocal leukoencephalopathy (PML) or unexplained new-onset or deteriorating neurologic signs and symptoms
* Participants with patient health questionnaire (PHQ-9) score =10, that in the opinion of a mental healthcare professional pose a serious suicide risk, or have any history of suicidal behavior in the last 6 months and/or any suicidal ideation in the last 2 months, or who in the investigator's judgment, poses a significant suicide risk.
* Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years
* Breast cancer within the past 10 years
* Major surgery (including joint surgery) within 3 months prior to screening or planned during the duration of the study
* An active infection, or a history of infections
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
11/09/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
13/12/2028
Query!
Actual
Query!
Sample size
Target
440
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
SA,WA
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Adelaide
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Woodville
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Spearwood
Query!
Recruitment postcode(s) [1]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
5011 - Woodville
Query!
Recruitment postcode(s) [3]
0
0
6163 - Spearwood
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
New York
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
North Carolina
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Pennsylvania
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Texas
Query!
Country [7]
0
0
Argentina
Query!
State/province [7]
0
0
Buenos Aires
Query!
Country [8]
0
0
Argentina
Query!
State/province [8]
0
0
Ciudad Autonoma Buenos Aires
Query!
Country [9]
0
0
Argentina
Query!
State/province [9]
0
0
Ciudad Autonoma de Buenos Aires
Query!
Country [10]
0
0
Argentina
Query!
State/province [10]
0
0
Cordoba
Query!
Country [11]
0
0
Argentina
Query!
State/province [11]
0
0
Mendoza
Query!
Country [12]
0
0
Argentina
Query!
State/province [12]
0
0
Rosario
Query!
Country [13]
0
0
Argentina
Query!
State/province [13]
0
0
San Miguel de TucumAn
Query!
Country [14]
0
0
Argentina
Query!
State/province [14]
0
0
Santa Fe
Query!
Country [15]
0
0
Belgium
Query!
State/province [15]
0
0
Bruxelles
Query!
Country [16]
0
0
Belgium
Query!
State/province [16]
0
0
Namur
Query!
Country [17]
0
0
Brazil
Query!
State/province [17]
0
0
Barra Mansa
Query!
Country [18]
0
0
Brazil
Query!
State/province [18]
0
0
Porto Alegre
Query!
Country [19]
0
0
Brazil
Query!
State/province [19]
0
0
Sao Jose Do Rio Preto
Query!
Country [20]
0
0
Brazil
Query!
State/province [20]
0
0
SAo Paulo
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Quebec
Query!
Country [22]
0
0
China
Query!
State/province [22]
0
0
Beijing
Query!
Country [23]
0
0
China
Query!
State/province [23]
0
0
Chengdu
Query!
Country [24]
0
0
China
Query!
State/province [24]
0
0
Guangzhou
Query!
Country [25]
0
0
China
Query!
State/province [25]
0
0
Hangzhou
Query!
Country [26]
0
0
China
Query!
State/province [26]
0
0
Mianyang
Query!
Country [27]
0
0
China
Query!
State/province [27]
0
0
Nanjing
Query!
Country [28]
0
0
China
Query!
State/province [28]
0
0
Nanning
Query!
Country [29]
0
0
China
Query!
State/province [29]
0
0
Shanghai
Query!
Country [30]
0
0
China
Query!
State/province [30]
0
0
Suzhou
Query!
Country [31]
0
0
China
Query!
State/province [31]
0
0
Tianjin
Query!
Country [32]
0
0
China
Query!
State/province [32]
0
0
ZhuZhou
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Angers Cedex 9
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Le Kremlin-bicetre
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Lille
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Pessac cedex
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Rouen Cedex
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Toulouse cedex 9
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Essen
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Minden
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Wuerzburg
Query!
Country [42]
0
0
Greece
Query!
State/province [42]
0
0
Athens
Query!
Country [43]
0
0
Greece
Query!
State/province [43]
0
0
Larissa
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Ancona
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Milano
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Modena
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
Napoli
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
Padova
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Pavia
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
Pisa
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Roma
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Udine
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Verona
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Aichi
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Fukuoka
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Hiroshima
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Hokkaido
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Kanagawa
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Miyagi
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Miyazaki
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Saitama
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Tokyo
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Tottori
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Yamanashi
Query!
Country [65]
0
0
Korea, Republic of
Query!
State/province [65]
0
0
Bucheon Kyunggi-Do
Query!
Country [66]
0
0
Korea, Republic of
Query!
State/province [66]
0
0
Seoul
Query!
Country [67]
0
0
Korea, Republic of
Query!
State/province [67]
0
0
Suwon Kyunggi-do
Query!
Country [68]
0
0
Korea, Republic of
Query!
State/province [68]
0
0
Yongsan-Ku Seoul
Query!
Country [69]
0
0
Mexico
Query!
State/province [69]
0
0
Chihuahua
Query!
Country [70]
0
0
Mexico
Query!
State/province [70]
0
0
Ciudad de Mexico
Query!
Country [71]
0
0
Mexico
Query!
State/province [71]
0
0
Guadalajara
Query!
Country [72]
0
0
Mexico
Query!
State/province [72]
0
0
Merida
Query!
Country [73]
0
0
Netherlands
Query!
State/province [73]
0
0
Maastricht
Query!
Country [74]
0
0
Netherlands
Query!
State/province [74]
0
0
Rotterdam
Query!
Country [75]
0
0
Netherlands
Query!
State/province [75]
0
0
Utrecht
Query!
Country [76]
0
0
Panama
Query!
State/province [76]
0
0
Ciudad de Panama
Query!
Country [77]
0
0
Panama
Query!
State/province [77]
0
0
Panama City
Query!
Country [78]
0
0
Panama
Query!
State/province [78]
0
0
Panama
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
Barcelona
Query!
Country [80]
0
0
Spain
Query!
State/province [80]
0
0
COrdoba
Query!
Country [81]
0
0
Spain
Query!
State/province [81]
0
0
Granada
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Madrid
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Malaga
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Pamplona
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Sevilla
Query!
Country [86]
0
0
United Kingdom
Query!
State/province [86]
0
0
Birmingham
Query!
Country [87]
0
0
United Kingdom
Query!
State/province [87]
0
0
Leicester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Interstitial lung disease (ILD) is a lung condition resulting in inflammation and stiffening of the lung, often associated with connective tissue diseases (CTDs). ILD causes reduction in lung volume, shortness of breath, cough and fatigue therefore has high impact on quality of life and is also the leading cause of death in participants with these conditions. The study will assess whether treatment of CTD-ILD participants with belimumab in addition to standard therapy will result in the stabilization and/or improvement of lung function and improve symptoms associated with ILD with an acceptable safety profile.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06572384
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
US GSK Clinical Trials Call Center
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
877-379-3718
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06572384
Download to PDF